CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work
Sterling Pharma Solutions has announced the acquisition of ADC Bio, a UK-based company that specializes in antibody drug conjugates. ADC’s Wales manufacturing facility will rebrand to become part of the Sterling network, the companies said.
ADC will start work as part of the Sterling network as early as 2022. The move allows Sterling to integrate the new facility’s highly potent API capabilities to develop and manufacture toxin linkers, according to a release.